Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries
25 juil. 2022 01h00 HE
|
Pluristem Therapeutics, Inc.
As of July 26, 2022, Pluri’s stock will trade under the symbol PLURThe new name reflects the Company’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing...
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
13 juil. 2022 06h00 HE
|
Pluristem Therapeutics, Inc.
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration:...
Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership
28 mars 2022 03h00 HE
|
Pluristem Therapeutics, Inc.
Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at:...
Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions
23 mars 2022 07h30 HE
|
Pluristem Therapeutics, Inc.
Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced...
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
08 mars 2022 07h12 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”),...
Pluristem CEO Issues Shareholder Update
02 mars 2022 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief...
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
24 févr. 2022 07h00 HE
|
Pluristem Therapeutics, Inc.
Pluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022, cementing an innovative partnership in the fast-growing industry of food techPluristem and Tnuva are...
Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform
10 janv. 2022 03h00 HE
|
Pluristem Therapeutics, Inc.
Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power multipliers in consumer-packaged goods, research and...
Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19
27 déc. 2021 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced topline results from its...
Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
15 nov. 2021 07h10 HE
|
Pluristem Therapeutics, Inc.
Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event...